RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
Thromb Haemost 1988; 59(02): 329-332
DOI: 10.1055/s-0038-1642781
DOI: 10.1055/s-0038-1642781
Original Articles
Daytime Fluctuations in Blood of Tissue-Type Plasminogen Activator (t-PA) and Its Fast-Acting Inhibitor (PAI-1)
Weitere Informationen
Publikationsverlauf
Received 24. August 1987
Accepted after revision 31. Dezember 1987
Publikationsdatum:
21. Mai 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198802/lookinside/thumbnails/10-1055-s-0038-1642781-1.jpg)
Summary
Circadian fluctuation in blood fibrinolytic activity was studiedin 10 volunteers in the day-time period at 09.00, 12.00 and15.0 h. Activity of tissue-type plasminogen activator (t-PA) wasfound to increase from 09.00 to 15.00 h in accordance with knownresults with global assays of blood activity.
-
References
- 1 Fearnley GR, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolyticrhythm; with a simple method of measuring natural fibrinolysis. Clin Sci 1957; 16: 645-650
- 2 Rosing DR, Brakman P, Redwood DR, Goldstein RE, Beiser GD, Astrup T, Epstein SE. Blood fibrinolytic activity in man Diurnal variation and theresponse to varying intensities of exercise. Circ Res 1970; 27: 171-184
- 3 Cepelak V, Barcal R, Cepelakova H, Mayer O. Circadian rhythm of fibrinolysisIn: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1978. 3. 571-578
- 4 Simpson HC R, Mann J I, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. The Lancet 1983; i: 786-790
- 5 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasmino-gen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
- 6 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
- 7 Kluft C, Verheijen JH, Chang GT G, Jie AF H, Onkelinx C. Diurnalfluctuations in the activity in blood of the fast-acting t-PA inhibitor. Haemostasis 1984; 14: 100 (Abstr)
- 8 Kluft C, Verheijen JH, Rijken DC, Chang GT G, Jie AF H, Onkelinx C. Diurnal fluctuations in the activity in blood of the fast-acting t-PA inhibitor. In:Progress in Fibrinolysis. Davidson JF, Donati MB, Coccheri S. (Eds) ChurchillLivingstone; Edinburgh: 1985. 7. 117-119
- 9 Kluft C, Brakman P, Veldhuijzen-Stolk EC. Screening of fibrinolytic activity inplasma euglobulin fractions on the fibrin plate. In: Progress in ChemicalFibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1976. 2. 57-64
- 10 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogenactivator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
- 11 Gaffney PJ, Curtis AD. A collaborative study of a proposed internationalstandard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
- 12 Rijken DC, Van Hinsbergh VW M, Sens EH C. Quantitation of tissue-typeplasminogen activator in human endothelial cell cultures by use of an enzymeimmunoassay. Thromb Res 1984; 33: 145-153
- 13 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. ThrombHaemostas 1984; 51: 392-5
- 14 Rijken DC, Sprengers ED, Van der Hoeven RJ, Jansen BG. An enzymeimmunoassay for endothelial cell-type plasminogen activator inhibitor (PAI). Fibrinolysis 1986; Suppl (Suppl. 01) 141 (Abstr)
- 15 Kluft C, Jie AF H, Sprengers ED, Verheijen JH. Identification of a reversibleinhibitor of plasminogen activators in blood plasma. FEBS Lett 1985; 190: 315-318
- 16 Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysisvariables in the characterization of a risk group for myocardial reinfarction. ActaMed Scand 1987; 221: 149-153
- 17 Kluft C. Cl-Inactivator-resistant fibrinolytic activity in plasma euglobulin frac-tions: its relation to vascular activator in blood and its role in euglobulinfibrinolysis. Thromb Res 1978; 13: 135-151
- 18 Kluft C, Jie AF H, Allen RA. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemostas 1983; 50: 518-523
- 19 Neerstrand H, Ostergaard P, Bergqvist D, Matzch T, Hedner U. t-PA inhibitor, t-PA:Agplasminogen and a2-antiplasmin after low molecular weight heparin orstandard heparin. Fibrinolysis 1987; 1: 39-43
- 20 Kluft C, Jie AF H. Underestimation of tissue-type plasminogen activator activityin plasma when euglobulin fractions are used for assessment. Fibrinolysis 1986; Suppl (Suppl. 01) 147-(Abstr)
- 21 Verheijen JH, Rijken DC, Chang GT G, Preston FE, Kluft C. Modulation ofrapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemo-stas 1984; 51: 396-397
- 22 Rijken DC, Emeis JJ. Hepatic clearance of tissue-type plasminogen activatorand some of its derivatives. Eur J Clin Invest 1986; 16: A18 (Abstr 95)
- 23 Jespersen J. The diurnal increase in euglobulin fibrinolytic activity in womenusing oral contraceptives and in normal womenand the generation of intrinsicfibrinolytic activity. Thromb Haemostas 1986; 56: 183-8
- 24 Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. Impairment ofthe diurnal fibrinolytic response in man Effects of agingtype IV hyperlipo-proteinemiaand coronary artery disease. Circulation 1973; 32: 752-758
- 25 Marshall J. Diurnal variation in occurrences of strokes. Stroke 1977; 88: 230-231
- 26 Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Klangos I, Stone PH. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131-138